![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, December 22, 2016 10:27:21 PM
Pharmacyte Biotech Inc (OTCMKTS:PMCB) Progresses With Patients Enrollment Process In Pancreatic Cancer Clinical Trial
Pharmacyte Biotech Inc (OTCMKTS:PMCB) is successfully making progress with its enrollments process in a pivotal clinic trial targeting advanced, inoperable pancreatic cancer. It started with the enrollment after the FDA approved its pre-IND request meeting. A host of oncologists, clinicians and renowned scientists will discuss with the U.S. regulatory agency on the related study and gain valuable insight on Investigational New Drug application. This is a step that comes after the enrollment process step in a clinical study.
What is the progress?
With Pharmacyte Biotech and a team of famous oncologists all set to introduce a clinical trial in the United States as well as Europe, the FDA’s IND step is vital to accomplishing the goal. After the IND procedure runs its course, stockholders need to be prepared for a 6-month hard stop in the reported clinical trial could lead in the way of report to the industry. Believing the past performance recorded in previous Pharmacyte clinical trials, the company is quite close to making a powerful story for people with severe, inoperable pancreatic cancer.
The company’s pancreatic cancer therapy has been awarded the Orphan Drug Designation, so if it can repeat the strong performance of earlier clinical trials, there is a strong chance that it could successfully get the breakthrough therapy status from the FDA.
There are two segments specifically that could drive to this designation, and they are the quality of life and how well Pharmacyte’s treatment can shrink inoperable tumors for making them operable. In earlier studies, the firm’s treatment did enhance the quality of life and presented the capacity to shrink a pancreatic tumor.
Pharmacyte has acknowledged that there is presently an unmet medical requirement in a segment of locally advanced pancreatic cancer. There are patients that no longer get any benefit from taking of the combination of Abraxane® and gemcitabine after almost 4-6 months of treatment.
https://wallstreetpr.com/pharmacyte-biotech-inc-otcmktspmcb-progresses-with-patients-enrollment-process-in-pancreatic-cancer-clinical-trial-37682
Go $PCMB... Why not us this time, right? Let's go...
Recent PMCB News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 07/29/2024 08:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:59:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:35 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:05:04 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/30/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:40:20 PM
- PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease • Business Wire • 05/21/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
FEATURED Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • Jul 29, 2024 9:07 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM